Knight Capital Group’s Biogen BIIB Stock Holding History

Knight Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$1.64M	Buy	+7,602	New	+$1.62M	0.03%	656

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Knight Capital Group's BIIB Position: Q2 2013 in Review

Knight Capital Group opened a new position in Biogen (BIIB) in Q2 2013: 7,602 shares worth $1.64M. The stake represents 0.03% of the portfolio and ranks #656 among its holdings.

646 funds tracked by Wall St. Rank hold BIIB as of Q2 2013.

Knight Capital Group held 7,602 shares of Biogen worth $1.64M as of Q2 2013.
Biogen was a new Knight Capital Group position in Q2 2013.
Biogen made up 0.03% of Knight Capital Group's portfolio in Q2 2013, its #656 holding.
646 funds tracked by Wall St. Rank held Biogen as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.